BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Zhang Y, Zou JY, Wang Z, Wang Y. Fruquintinib: a novel antivascular endothelial growth factor receptor tyrosine kinase inhibitor for the treatment of metastatic colorectal cancer. Cancer Manag Res. 2019;11:7787-7803. [PMID: 31496821 DOI: 10.2147/cmar.s215533] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 4.0] [Reference Citation Analysis]
Number Citing Articles
1 Matsuoka T, Yashiro M. Molecular-targeted therapy toward precision medicine for gastrointestinal cancer: Current progress and challenges. World J Gastrointest Oncol 2021; 13(5): 366-390 [PMID: 34040699 DOI: 10.4251/wjgo.v13.i5.366] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
2 Alsaif NA, Taghour MS, Alanazi MM, Obaidullah AJ, Al-Mehizia AA, Alanazi MM, Aldawas S, Elwan A, Elkady H. Discovery of new VEGFR-2 inhibitors based on bis([1, 2, 4]triazolo)[4,3-a:3',4'-c]quinoxaline derivatives as anticancer agents and apoptosis inducers. J Enzyme Inhib Med Chem 2021;36:1093-114. [PMID: 34056992 DOI: 10.1080/14756366.2021.1915303] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
3 Kasprzak A. Angiogenesis-Related Functions of Wnt Signaling in Colorectal Carcinogenesis. Cancers (Basel) 2020;12:E3601. [PMID: 33276489 DOI: 10.3390/cancers12123601] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
4 Ayala-Aguilera CC, Valero T, Lorente-Macías Á, Baillache DJ, Croke S, Unciti-Broceta A. Small Molecule Kinase Inhibitor Drugs (1995-2021): Medical Indication, Pharmacology, and Synthesis. J Med Chem 2021. [PMID: 34624192 DOI: 10.1021/acs.jmedchem.1c00963] [Reference Citation Analysis]
5 Shu Y, Zheng S. Case Report: Severe Rashes Associated With Fruquintinib in a Patient With Metastatic Colorectal Cancer. Front Oncol 2021;11:688231. [PMID: 34290985 DOI: 10.3389/fonc.2021.688231] [Reference Citation Analysis]
6 Zhang Y, Zou JY, Xu YY, He JN. Fruquintinib beneficial in elderly patient with neoplastic pericardial effusion from rectal cancer: A case report. World J Clin Cases 2021; 9(21): 6170-6177 [PMID: 34368339 DOI: 10.12998/wjcc.v9.i21.6170] [Cited by in CrossRef: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Lu S, Zhou JY, Niu XM, Zhou JY, Jian H, Yin HY, Guan S, Wang LF, Li K, He J, Su WG. Fruquintinib with gefitinib as first-line therapy in patients carrying EGFR mutations with advanced non-small cell lung cancer: a single-arm, phase II study. Transl Lung Cancer Res 2021;10:839-54. [PMID: 33718026 DOI: 10.21037/tlcr-20-1028] [Reference Citation Analysis]
8 Bai M, Li ZG, Ba Y. Influence of KDR Genetic Variation on the Efficacy and Safety of Patients with Chemotherapy Refractory Metastatic CRC Who Received Apatinib Treatment. Int J Gen Med 2021;14:1041-55. [PMID: 33790633 DOI: 10.2147/IJGM.S300968] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Qin S, Xu RH, Shen L, Xu J, Bai Y, Yang L, Deng Y, Chen ZD, Zhong H, Pan H, Guo W, Shu Y, Yuan Y, Zhou J, Xu N, Liu T, Ma D, Wu C, Cheng Y, Chen D, Li W, Sun S, Yu Z, Cao P, Chen H, Wang J, Wang S, Wang H, Wang N, Zhang B, Zhang Q, Su W, Guo X, Li J. Subgroup Analysis by Liver Metastasis in the FRESCO Trial Comparing Fruquintinib versus Placebo Plus Best Supportive Care in Chinese Patients with Metastatic Colorectal Cancer. Onco Targets Ther 2021;14:4439-50. [PMID: 34408440 DOI: 10.2147/OTT.S307273] [Reference Citation Analysis]
10 Hebishy AMS, Abdelfattah MS, Elmorsy A, Elwahy AHM. Synthesis of novel bis‐ and poly(benzimidazoles) as well as bis‐ and poly(benzothiazoles) as anticancer agents. J Heterocyclic Chem 2020;57:2256-70. [DOI: 10.1002/jhet.3947] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
11 Nalli M, Puxeddu M, La Regina G, Gianni S, Silvestri R. Emerging Therapeutic Agents for Colorectal Cancer. Molecules 2021;26:7463. [DOI: 10.3390/molecules26247463] [Reference Citation Analysis]
12 Esteban-Villarrubia J, Soto-Castillo JJ, Pozas J, San Román-Gil M, Orejana-Martín I, Torres-Jiménez J, Carrato A, Alonso-Gordoa T, Molina-Cerrillo J. Tyrosine Kinase Receptors in Oncology. Int J Mol Sci 2020;21:E8529. [PMID: 33198314 DOI: 10.3390/ijms21228529] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]